Status:
UNKNOWN
The Safety of Chemotherapy for Patients With Gynecological Malignancy in High-risk Region of COVID-19
Lead Sponsor:
Tongji Hospital
Conditions:
Gynecological Cancer
Eligibility:
FEMALE
18-80 years
Brief Summary
A novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disease (COVID-19) emerged at December 2019 in Wuhan, China, and soon caused a large global outbreak. The delayed treatment for man...
Detailed Description
A novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2; previously provisionally named 2019 novel coronavirus or 2019-nCoV) disease (COVID-19) emerged at December 2019 in Wuhan, Hubei Pro...
Eligibility Criteria
Inclusion
- Patient is 18 to 80 years old female.
- Patient must have histologically confirmed either type of gynecological malignancies.
- Chemotherapy must be essential for the patient.
Exclusion
- Diagnosed or suspected patients with covid-19 pneumonia, according to the symptom, nucleic acid tests, antibody tests for SARS-CoV-2, or CT scan of the lungs.
- Patient has a prior SARS-CoV-2 infection without clinical cure for 28 days.
- Patient has close contact with diagnosed or suspected SARS-CoV-2 infected person within 14 days.
- Patient has inadequate general condition, severe complication or organ dysfunction not fit for chemotherapy (based on the judgment of researchers).
- Patient or the family refuses to sign the informed consent.
- Patient does not cooperate in following up.
Key Trial Info
Start Date :
July 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 10 2023
Estimated Enrollment :
305 Patients enrolled
Trial Details
Trial ID
NCT04341480
Start Date
July 1 2020
End Date
January 10 2023
Last Update
October 7 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China, 430030